Showing 8731-8740 of 9546 results for "".
- News You Can Use: Hydrafacial Offers Monthly Scholarships for Connect Certification Programhttps://practicaldermatology.com/news/news-you-can-use-hydrafacial-offers-monthly-scholarships-for-connect-certification-program/2460863/HydraFacial is now offering a scholarships for their Connect certification program The Connect certification program comprises business building, marketing, cross-selling, social media, networking, mentoring, and leadership in a 3-level program that includes video assessments
- Foods High in Sugar and Fat Disrupt the Gut Microbiome and Trigger Psoriasis Flareshttps://practicaldermatology.com/news/foods-high-in-sugar-and-fat-disrupt-the-gut-microbiome-and-trigger-psoriasis-flares/2460846/Diets rich in sugar and fat may lead to an imbalance in the gut’s microbial culture and contribute to inflammatory skin diseases such as psoriasis, according to a new study in the Journal o
- DermTech Fills Three Leadership Postshttps://practicaldermatology.com/news/dermtech-fills-three-leadership-posts/2460843/With three new appointments, DermTech has filled key leadership roles at the company. Loren Clarke, MD is now Chief Medical Officer, Ray Bassi is Vice President, Sales, and Patrick Johnson is Vice President, Information Technology and Digital Systems. Dr. Clarke, a board-ce
- CellFX from Pulse Biosciences Cleared in Canadahttps://practicaldermatology.com/news/cellfx-from-pulse-biosciences-cleared-in-canada/2460833/The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Puls
- Dermavant Submits NDA for Tapinarof for PsOhttps://practicaldermatology.com/news/dermavant-submits-nda-for-tapinarof-for-pso/2460820/Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severe plaque psoriasis in adult patients. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily,
- Medivir’s Remetinostat Shows Promise for SCChttps://practicaldermatology.com/news/medivirs-remetinostat-shows-promise-for-scc/2460807/Topical remetinostat gel performed well in a small investigator-initiated phase II clinical study of patients with squamous cell carcinoma. Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumors, including
- It’s Melanoma Monday! Focus on Preventionhttps://practicaldermatology.com/news/its-melanoma-monday-focus-on-prevention/2460792/With new data showing that one-third of Americans lack a basic understanding of skin cancer and sun protection, the American Academy of Dermatology’s annual Melanoma Monday takes on special significance.
- UCB: Bimekizumab PDUFA Date Set for Octoberhttps://practicaldermatology.com/news/ucb-bimekizumab-pdufa-set-for-october/2460787/The FDA's Prescription Drug User Fee Act (PDUFA) date for UCB’s Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is October 15, 2021, UCB has indicated. In a
- Pulse Biosciences Survey: Clearing Pigmented Lesions is No. 1 Priority for Manyhttps://practicaldermatology.com/news/pulse-biosciences-survey-clearing-pigmented-lesions-is-no-1-priority-for-many/2460786/A majority of patients with unwanted benign lesions are interested in a new procedure to clear these lesions, according to a new survey by Pulse Biosciences that was presented at the American Academy of Dermatology (AAD) Virtual Annual Meeting. A diverse sample of 405 aesthetic patients
- Minimizing Risks of Cosmetic Procedures in Patients with Darker Skin Typeshttps://practicaldermatology.com/news/minimizing-risks-of-cosmetic-procedures-in-patients-with-darker-skin-types/2460784/With cosmetic procedures in high demand during the pandemic, Cedars-Sinai dermatologist Jasmine Obioha, MD, has seen an unfortunate side effect: botched treatments for patients of color. When performed improperly, procedures such as chemical peels and laser hair removal can inflame and